Tamara Alagirova
CEO, founder
MONCYTE Health Oy
Helsinki, Finland
With over 15 years of international business experience in the health technology sector I have a background in pharma, surgery, medical devices and diagnostics.
My organisation
MONCYTE Health, established in 2024, is an early-stage Finnish health technology company developing a novel solution that integrates cellular diagnostics with robotics, high-resolution imaging, advanced software, and artificial intelligence. The focus of the solution is to uncover and analyze the cellular mechanisms driving inflammation within atherosclerotic plaque from a blood sample, a key factor in cardiovascular disease. This multidisciplinary approach enables a level of biological insight that current diagnostic methods do not provide, and supports the development of more targeted, effective care pathways. The technology is designed to generate new, clinically relevant data that benefits not only physicians in tailoring treatment decisions but also pharmaceutical companies developing next-generation cardiovascular and inflammation-modulating therapies.